Xenetic Biosciences, Inc.

Home
United States
Framingham, MA
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is

initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

08/07/2026

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

https://bit.ly/4z4Uf8T

08/06/2026

Xenetic Biosciences announced that its collaboration partner received approval from the Israeli Ministry of Health to conduct an investigator-initiated study evaluating DNase I in combination with anti-CD19 CAR-T cells for the treatment of large B-cell lymphoma.

Read more: https://bit.ly/4vXbzdo

07/28/2026

Never miss an update from us.

Subscribe to our email alerts for the latest company information.

Sign up here: https://bit.ly/3MTgAiR

07/20/2026

Did you know?

Pancreatic cancer is the 3rd deadliest cancer in the U.S., with a 5-year survival rate of just ~3% for patients diagnosed at advanced stages.

These shows the urgent need for innovative new treatment options.

07/09/2026

At Xenetic Biosciences, we are advancing innovative immune-oncology technologies designed to address hard-to-treat cancers.

Through our DNase platform, we are focused on improving treatment outcomes and advancing new possibilities for patients.

07/04/2026

Today, we're celebrating 250 years of American independence and the freedom to pursue bold ideas, scientific discovery and a better future for patients.

From all of us at Xenetic Biosciences, we wish you a safe, happy and meaningful Fourth of July.

06/29/2026

We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

06/23/2026

Each year, ~67,000 people are diagnosed and nearly 52,000 lose their lives to Pancreatic Cancer in the U.S., a stark reminder of the urgent unmet need.
is committed to advancing new approaches.

06/15/2026

Don’t miss an update from Xenetic Biosciences.
Subscribe to email alerts for the latest on clinical progress, company news and key announcements straight to your inbox.

https://bit.ly/3MTgAiR

06/05/2026

June is , a time to recognize and celebrate the millions of individuals whose journeys continue to inspire progress across cancer care and research.

At Xenetic, we remain committed to advancing innovative oncology approaches with the goal of helping improve outcomes for patients facing difficult-to-treat cancers.

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Want your practice to be the top-listed Clinic in Framingham?